HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
BBIO
BridgeBio Pharma Inc
Healthcare Biotechnology · California, USA · Reports in usd
Market Cap: $13.43B
Market Cap
$13.43B
Enterprise Val
$14.71B
P/E Ratio
-18.53
P/B Ratio
-6.44
Trailing PEG (1Y)
0.61
As Of
Apr 27, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value-$2.08B
Gross Margin94.74%
Profit Margin94.74%
Return on Equity38.89%
Return on Assets-74.43%
Current Ratio2.77
Debt/Equity-0.89
LT Debt/Equity-0.89
Revenue Per Share0.80

Income Statement

Dec 31, 2025
Revenue$154.2M
Cost of Revenue$8.1M
Gross Profit$146.1M
R&D$116.4M
SG&A$158.1M
Operating Expenses$285.6M
Operating Income-$139.6M
Interest Expense$11.6M
Tax Expense-$120.0K
Net Income-$192.9M
EPS (Basic)$-0.99
EPS (Diluted)$-0.99
EBIT-$181.3M
EBITDA-$178.5M
Consolidated Income-$194.6M
Non-Controlling Interests-$1.8M

Balance Sheet

Dec 31, 2025
Cash & Equivalents$570.1M
Accounts Receivable$139.4M
Inventory$26.8M
Current Assets$797.7M
LT Investments$80.0M
Property, Plant & Equipment$13.5M
Intangibles$28.1M
Non-Current Assets$138.3M
Total Assets$936.0M
Accounts Payable$36.2M
Current Debt$6.2M
Current Liabilities$288.0M
LT Debt$1.86B
Non-Current Liabilities$2.72B
Total Liabilities$3.01B
Total Debt$1.86B
Retained Earnings-$3.82B
Shareholder Equity-$2.09B
Shares Outstanding192,708,813

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$56.4M
Investing Cash Flow-$14.4M
Financing Cash Flow-$2.2M
CapEx-$33.0K
Free Cash Flow-$56.5M
Depreciation & Amort.$2.9M
Stock-Based Comp$34.6M
Acquisitions / Disposals$0.00
Investment Activity-$14.3M
Debt Issued/Repaid$0.00
Equity Issued/Repaid-$7.4M
Dividends Paid$0.00
Net Change in Cash-$73.0M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h